Two Israeli companies, OrSense and Glucon have presented good results of clinical tests at the American Diabetes Association's 66th Scientific Sessions, in Washington, D.C. This is considered to be one of the most important conferences in the field and Israel is considered a minor powerhouse for development of new diabetes monitoring technologies. OrSense and Glucon were the only companies to present clinical results in non-invasive blood sugar testing, one of the hot issues on the conference agenda and one of the big technological challenges in the field today. Globes Online (http://www.globes.co.il/serveen/globes/docview.asp?did=1000101681&fid=942)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
